Lintuzumab

Lintuzumab (HUM-195) is an anti-CD33 humanized monoclonal antibody. Lintuzumab reduces the production of TNFα-induced pro-inflammatory cytokines and chemokines by AML cells. Lintuzumab promotes tumor cell killing through antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) activities against MDR and MDR+ AML cell lines and primary AML patient samples. Lintuzumab enhances survival and reduces tumor burden in mice[1].

Product Specifications

CAS Number

[166089-32-3]

Product Name Alternative

SGN-33; HuM-195

UNSPSC

12352203

Target

Radionuclide-Drug Conjugates (RDCs) ; Transmembrane Glycoprotein

Type

Inhibitory Antibodies

Related Pathways

Antibody-drug Conjugate/ADC Related; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/lintuzumab.html

Purity

98.09

Solubility

H2O

Smiles

[Lintuzumab]

Molecular Weight

(145.24 kDa)

References & Citations

[1]Lintuzumab|[2]Sutherland, M. K., et al., (2009) . Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia. mAbs, 1 (5), 481–490.